Abstract
A multicenter randomized study comparing high dose of mitomycin and epirubicin given as hepatic intra-arterial chemotherapy (HIAC) combined with caval chemofiltration (CF) versus low doses of the same drugs in unresectable liver metastases from colorectal cancer showed a significant improvement in the survival rate of the 20 patients treated with high dose compared to the 22 patients treated with low doses with a 1 year survival of 69% vs 39%. The median survival was 17 vs 11 months and the responses were 65% vs 33%. Toxicity was colangitis in 50% of patients considered. The extrahepatic progression was similar in the two groups (7/20 vs 8/22).
| Original language | English |
|---|---|
| Pages (from-to) | 51-54 |
| Number of pages | 4 |
| Journal | Journal of Chemotherapy |
| Volume | 16 |
| Issue number | SUPPL. 5 |
| Publication status | Published - Nov 2004 |
Fingerprint
Keywords
- Chemofiltration
- Intra-arterial chemotherapy
- Liver metastases
ASJC Scopus subject areas
- Pharmacology (medical)
- Microbiology (medical)
Cite this
Hepatic intra-arterial chemotherapy (HIAC) of high dose mitomycin and epirubicin combined with caval chemofiltration versus prolonged low doses in liver metastases from colorectal cancer : A prospective randomized clinical study. / Fiorentini, Giammaria; Poddie, D. B.; Cantore, M.; Rossi, S.; Tumolo, S.; Dentico, P.; Bernardeschi, P.; Guadagni, S.; Rossi, G.; Valori, V. M.; De Simone, M.
In: Journal of Chemotherapy, Vol. 16, No. SUPPL. 5, 11.2004, p. 51-54.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Hepatic intra-arterial chemotherapy (HIAC) of high dose mitomycin and epirubicin combined with caval chemofiltration versus prolonged low doses in liver metastases from colorectal cancer
T2 - A prospective randomized clinical study
AU - Fiorentini, Giammaria
AU - Poddie, D. B.
AU - Cantore, M.
AU - Rossi, S.
AU - Tumolo, S.
AU - Dentico, P.
AU - Bernardeschi, P.
AU - Guadagni, S.
AU - Rossi, G.
AU - Valori, V. M.
AU - De Simone, M.
PY - 2004/11
Y1 - 2004/11
N2 - A multicenter randomized study comparing high dose of mitomycin and epirubicin given as hepatic intra-arterial chemotherapy (HIAC) combined with caval chemofiltration (CF) versus low doses of the same drugs in unresectable liver metastases from colorectal cancer showed a significant improvement in the survival rate of the 20 patients treated with high dose compared to the 22 patients treated with low doses with a 1 year survival of 69% vs 39%. The median survival was 17 vs 11 months and the responses were 65% vs 33%. Toxicity was colangitis in 50% of patients considered. The extrahepatic progression was similar in the two groups (7/20 vs 8/22).
AB - A multicenter randomized study comparing high dose of mitomycin and epirubicin given as hepatic intra-arterial chemotherapy (HIAC) combined with caval chemofiltration (CF) versus low doses of the same drugs in unresectable liver metastases from colorectal cancer showed a significant improvement in the survival rate of the 20 patients treated with high dose compared to the 22 patients treated with low doses with a 1 year survival of 69% vs 39%. The median survival was 17 vs 11 months and the responses were 65% vs 33%. Toxicity was colangitis in 50% of patients considered. The extrahepatic progression was similar in the two groups (7/20 vs 8/22).
KW - Chemofiltration
KW - Intra-arterial chemotherapy
KW - Liver metastases
UR - http://www.scopus.com/inward/record.url?scp=19944426129&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=19944426129&partnerID=8YFLogxK
M3 - Article
C2 - 15675479
AN - SCOPUS:19944426129
VL - 16
SP - 51
EP - 54
JO - Journal of Chemotherapy
JF - Journal of Chemotherapy
SN - 1120-009X
IS - SUPPL. 5
ER -